The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses practice-changing abstracts in multiple myeloma presented at ASH 2019.
Prof. Mohty discusses important trials in patients with relapsed/refractory multiple myeloma such as the CAR T trials CARTITUDE-1 and LEGEND-2, studies involving bispecific antibodies such as CC-93269, and new monoclonal antibodies such as TAK-079. Whilst the bispecific antibodies may challenge the role of CAR T in myeloma, Prof. Mohty notes that we will likely need to use all these tools, in different patient populations. Next, Prof. Mohty discusses key trials in smoldering myeloma, especially in high-risk patients, such as GEM-CESAR, and concludes by talking about advances in frontline therapy presented at ASH such as the ALCYONE trial.